Drug Trial Radar · NCT06790394
Test-retest Study With [18F]FBB in Cardiac Amyloidosis
Last checked: Nov 20, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
15
Actual
Start
Oct 21, 2025
Primary completion
Oct 7, 2026
Study completion Oct 7, 2026
Sponsor
- Lead sponsor
- Lantheus Germany GmbHIndustry
- Sponsor type
- Industry
- Collaborators
- pharmtrace
- First posted
- Jan 24, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Diagnostic
- FDA-regulated drug
- No
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is an open-label study to evaluate and characterize test-retest reliability of \[18F\]florbetaben PET in subjects with AL-CA and ATTR-CA compared to non-CA subjects. Quantification of the \[18F\]florbetaben parameters related to the deposition of amyloid in the heart (such as Myocardial Tracer Retention (MTR) or Retention Index (RI)), and the variability in these parameters after repeated imaging will be evaluated. Measurement of blood metabolites and comparison of invasive with non-invasive quantification of \[18F\]florbetaben uptake in the heart will be performed.
Conditions
- Cardiac Amyloidosis
Interventions
Florbetaben F18Drug
Florbetaben F18 is a radioactive diagnostic agent being developed for the indication of PET imaging of the heart to detect amyloid pathology. All patients will receive two administrations of Florbetaben F18 at a radioactive dose of 300 megabecquerel (MBq).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Test-Retest variability of cardiac [18F]florbetaben PET uptakeTime frame: The duration of the study for participants may be up to 73 days.
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Royal Free Hospital
London, United Kingdom
King's College London
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.